Every burden of illness study we run quantifies the clinical, humanistic, and economic impact of disease.

Understanding disease burden is fundamental to healthcare planning, resource allocation, product development, and public health interventions.
Our disease burden studies help quantify the full impact of diseases on patients, healthcare systems, and society.
Evaluate:
Assess:
Analyze:
Evaluate patient impact including quality-of-life considerations.
Quality of life is assessed alongside the clinical and economic picture.
Burden evidence supports planning and decisions across healthcare.
Population Health AnalyticsIdentify opportunities to improve outcomes at scale through advanced healthcare analytics.Learn more
Patient Journey AnalyticsUnderstand how patients move through diagnosis, treatment, disease progression, and healthcare systems.Learn more
Comparative Effectiveness ResearchAssess how treatments perform against available alternatives in real-world settings.Learn moreShort answers about epidemiology and real-world research.
Have a different question?
Our epidemiologists can talk through your research question and data needs.
A burden of illness study quantifies the impact of a disease on patients, healthcare systems and society, across epidemiological, clinical, economic and humanistic measures.
A cost of illness study estimates the economic impact of a disease, including direct healthcare costs, hospitalizations, emergency visits and medication expenditures.
Burden of disease is measured with incidence, prevalence, mortality and survival, alongside complications, comorbidities, costs and quality-of-life considerations.
Humanistic burden describes how a disease affects patients’ lives, including quality of life, daily functioning and wellbeing.
Disease burden studies support market opportunity assessments, public health planning, value demonstration and medical affairs strategy.
Discover how Evimed Health can help transform healthcare data into meaningful evidence that improves healthcare decision-making.